Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Debt (2016 - 2025)

Historic Total Debt for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $19.1 million.

  • Aytu Biopharma's Total Debt rose 3628.44% to $19.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $19.1 million, marking a year-over-year increase of 3628.44%. This contributed to the annual value of $20.0 million for FY2025, which is 5037.67% up from last year.
  • Per Aytu Biopharma's latest filing, its Total Debt stood at $19.1 million for Q4 2025, which was up 3628.44% from $25.3 million recorded in Q3 2025.
  • Aytu Biopharma's 5-year Total Debt high stood at $25.3 million for Q3 2025, and its period low was $13.3 million during Q2 2024.
  • For the 5-year period, Aytu Biopharma's Total Debt averaged around $17.8 million, with its median value being $16.8 million (2021).
  • Its Total Debt has fluctuated over the past 5 years, first skyrocketed by 161568.23% in 2021, then crashed by 3053.83% in 2024.
  • Aytu Biopharma's Total Debt (Quarter) stood at $16.5 million in 2021, then soared by 33.33% to $22.0 million in 2022, then decreased by 27.13% to $16.0 million in 2023, then dropped by 12.55% to $14.0 million in 2024, then surged by 36.28% to $19.1 million in 2025.
  • Its last three reported values are $19.1 million in Q4 2025, $25.3 million for Q3 2025, and $20.0 million during Q2 2025.